|
[1]
|
Bhardwaj, A., Jindal, A., Arora, V., Rajan, V., Bhadoria, A.S., Kumar, G., et al. (2018) Natural History of Patients with Compensated Cirrhosis and a Hepatic Venous Pressure Gradient > 20 mmHg: A Prospective Longitudinal Cohort Study. Journal of Hepatology, 68, S716-S717. [Google Scholar] [CrossRef]
|
|
[2]
|
徐京杭, 于岩岩, 徐小元. 肝硬化逆转及再代偿相关研究进展[J]. 中华肝脏病杂志, 2023, 31(7): 673-676.
|
|
[3]
|
Liaw, Y.F., Sheen, I.S., Lee, C.M., Akarca, U.S., Papatheodoridis, G.V., Wong, F.S., et al. (2011) Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease. Hepatology, 53, 62-72. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. (2016) Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 65, 741-747. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669.
|
|
[6]
|
Kim, T.H., Um, S.H., Lee, Y., Yim, S.Y., Jung, Y.K., Seo, Y.S., et al. (2021) Determinants of Re‐Compensation in Patients with Hepatitis B Virus‐Related Decompensated Cirrhosis Starting Antiviral Therapy. Alimentary Pharmacology & Therapeutics, 55, 83-96. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Premkumar, M., et al. (2023) Recompensation of Chronic Hepatitis c-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Real-World Data from the Punjab HCV Elimination Model. Hepatology, 78, S10-S11.
|
|
[8]
|
中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.
|
|
[9]
|
王柏凯, 徐莹, 俞骁珺, 等. 十一种临床评分预测肝硬化伴急性上消化道出血6周死亡风险[J]. 胃肠病学和肝病学杂志, 2023, 32(3): 282-288.
|
|
[10]
|
Villanueva, C., Albillos, A., Genescà, J., Abraldes, J.G., Calleja, J.L., Aracil, C., et al. (2015) Development of Hyperdynamic Circulation and Response to β‐Blockers in Compensated Cirrhosis with Portal Hypertension. Hepatology, 63, 197-206. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, Y., Liu, X., Li, S., Lin, C., Ye, Q., Wang, Y., et al. (2023) Risk of HCC Decreases in HBV-Related Patients with Cirrhosis Acquired Recompensation: A Retrospective Study Based on Baveno VII Criteria. Hepatology Communications, 8, e0355. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Goh, X.E., Goh, M.X., Chen, V.L., Garcia-Tsao, G., Abraldes, J.G. and Wong, Y.J. (2026) Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 24, 911-922. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
许丹青, 张映媛, 木唤, 等. 失代偿期乙型肝炎肝硬化患者再代偿的影响因素分析[J]. 临床肝胆病杂志, 2025, 41(7): 1364-1370.
|
|
[14]
|
阮佳佳, 温世飞, 王霞, 等. 首次失代偿期乙型肝炎肝硬化患者获得再代偿的影响因素分析[J]. 临床肝胆病杂志, 2022, 38(8): 1796-1800.
|
|
[15]
|
Chen, Y., Wen, H., Li, Y., Zhang, W., Mao, T., Jiang, C., et al. (2025) Recompensation in Patients with Autoimmune Hepatitis-Related Decompensated Cirrhosis Following Immunosuppressive Therapy. JHEP Reports, 7, Article ID: 101496. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
朱宁宁, 焦淑宁, 张域爽, 等. 乙型肝炎肝硬化失代偿期患者再代偿的影响因素及其预测效能分析[J]. 山东医药, 2025, 65(6): 67-72.
|
|
[17]
|
王菁菁, 刘丽改, 谢雯. 白蛋白生理功能再认识[J]. 临床肝胆病杂志, 2025, 41(3): 404-408.
|
|
[18]
|
Chang, M., Cheng, J., Chien, R. and Liaw, Y. (2020) Hepatitis Flares Are Associated with Better Outcomes than No Flare in Patients with Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 18, 2064-2072.e2. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., et al. (2024) Predictive Factors for Decompensating Events in Patients with Cirrhosis with Primary Biliary Cholangitis under Different Lines of Therapy. Hepatology, 80, 791-806. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
高国全, 汤其群. 生物化学与分子生物学[M]. 第10版. 北京: 人民卫生出版社, 2024: 182-186.
|
|
[21]
|
张兴, 胡洋洋, 罗越, 等. 线粒体DNA在慢性肝病发病机制中作用的研究进展[J]. 中华肝脏病杂志, 2022, 30(4): 447-451.
|
|
[22]
|
希古日干, 苏雅, 佟静, 等. 终末期肝病模型(MELD)评分在终末期肝病中的应用[J]. 临床肝胆病杂志, 2025, 41(3): 556-560.
|
|
[23]
|
Hofer, B.S., Simbrunner, B., Hartl, L., Jachs, M., Balcar, L., Paternostro, R., et al. (2023) Hepatic Recompensation According to Baveno VII Criteria Is Linked to a Significant Survival Benefit in Decompensated Alcohol‐Related Cirrhosis. Liver International, 43, 2220-2231. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Peng, Y., Qi, X. and Guo, X. (2016) Child-Pugh versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine, 95, e2877. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
万学红, 卢雪峰. 诊断学[M]. 第10版. 北京: 人民卫生出版社, 2024: 275.
|
|
[26]
|
杨志慧, 陈美娟, 张濛销, 等. 多维度肝功能评估预测肝硬化再代偿研究进展[J]. 临床军医杂志, 2026, 54(2): 111-114.
|
|
[27]
|
Xavier, S.A., Vilas-Boas, R., Boal Carvalho, P., Magalhães, J.T., Marinho, C.M. and Cotter, J.B. (2018) Assessment of Prognostic Performance of Albumin-Bilirubin, Child-Pugh, and Model for End-Stage Liver Disease Scores in Patients with Liver Cirrhosis Complicated with Acute Upper Gastrointestinal Bleeding. European Journal of Gastroenterology & Hepatology, 30, 652-658. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Liu, Y., Wu, S., Cai, S. and Xie, B. (2024) The Prognostic Evaluation of ALBI Score in Endoscopic Treatment of Esophagogastric Varices Hemorrhage in Liver Cirrhosis. Scientific Reports, 14, Article No. 780. [Google Scholar] [CrossRef] [PubMed]
|